ACRS VS CVM Stock Comparison

Performance

ACRS
10/100

ACRS returned -96.22% in the last 12 months. Based on SPY's performance of -11.17%, its performance is below average giving it a score of 10 of 100.

CVM
10/100

CVM returned -64.83% in the last 12 months. Based on SPY's performance of -20.72%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

ACRS
92/100

6 analysts offer 12-month price targets for ACRS. Together, they have an average target of 25, the most optimistic target put ACRS at 25 within 12-months and the most pessimistic has ACRS at 25.

CVM
50/100

1 analysts offer 12-month price targets for CVM. Together, they have an average target of 0, the most optimistic target put CVM at 0 within 12-months and the most pessimistic has CVM at 0.

Sentiment

ACRS
69/100

ACRS had a bullish sentiment score of 68.61% across Twitter and StockTwits over the last 12 months. It had an average of 32.27 posts, 12.68 comments, and 65.86 likes per day.

CVM
69/100

CVM had a bullish sentiment score of 69.42% across Twitter and StockTwits over the last 12 months. It had an average of 18.88 posts, 118.68 comments, and 270.58 likes per day.

Technicals

ACRS
14/100

ACRS receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

CVM
10/100

CVM receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

ACRS
10/100

ACRS has missed earnings 8 times in the last 20 quarters.

CVM
10/100

CVM has missed earnings 13 times in the last 20 quarters.

Profit

ACRS
10/100

Out of the last 20 quarters, ACRS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CVM
10/100

Out of the last 20 quarters, CVM has had 1 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ACRS
42/100

ACRS has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

CVM
70/100

CVM has had a higher than average amount of volatility over the last 12 months giving it a score of 70 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Aclaris Therapeutics, Inc. Summary

Nasdaq / ACRS

Healthcare

Medical - Diagnostics & Research

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Cel-Sci Corporation Summary

Healthcare

Biotechnology

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Power up your portfolio